Forest Labs News

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Ironwood Pharmaceuticals, Inc.

The firm issued an underperform rating and a $27.00 target price on the stock. Shares of Forest Laboratories opened at 38.11 on Thursday.

This morning, JMP downgraded shares of Micron from outperform to market perform citing valuation.

StockCall.com Provides Stock Research on Delcath Systems Inc., Akorn Inc., Astex Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., and Forest Laboratories Inc.

KING OF PRUSSIA, Pa. & NEW YORK -- -- Trevena Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptors biased ligands, and Forest Laboratories Holding Limited , a subsidiary of Forest Laboratories, Inc.

's stock had its "corporate" rating reaffirmed by FinnCap in a research note issued on Wednesday, Analyst Ratings Network.com reports.

Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can't afford to miss.

Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial.

's stock had its "equal weight" rating reaffirmed by Barclays Capital in a research note issued on Thursday, Analyst Ratings.Net reports.

ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.

's stock had its "hold" rating reiterated by equities research analysts at Deutsche Bank in a research note issued to investors on Wednesday, StocKRatingsNetwork.com reports.

's stock had its "neutral" rating restated by Zacks in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork.com reports.

THE SPARK: The Cambridge, Mass., company reported a bigger loss and less revenue than analysts expected.

Francis I. Perier - Chief Financial Officer, Executive Vice President of Finance & Administration and Member of Disclosure, Legal Compliance & Risk Management Committee Marco Taglietti - Senior Vice President of Research & Development, Member of Disclosure, Legal Compliance & Risk Management Committee and President of Forest Research Institute Good ... (more)

Forest Laboratories issued its quarterly earnings data on Tuesday. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.16 by $0.01, Analyst Ratings.Net reports.

Forest Laboratories issued an update on its FY14 earnings guidance on Tuesday morning.

Forest Laboratories, Inc. , an international pharmaceutical manufacturer and marketer, today announced that reported diluted earnings per share equaled $0.17 in the fourth quarter of fiscal 2013.